{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:45:07Z","timestamp":1791344707779,"version":"4.3.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/nrclinonc.2011.63","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T07:03:36Z","timestamp":1303801416000},"page":"479-491","source":"Crossref","is-referenced-by-count":254,"title":["Treatment of multiple myeloma"],"prefix":"10.1038","volume":"8","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,26]]},"reference":[{"key":"BFnrclinonc201163_CR1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860\u20131873 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","volume":"80","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. & Kyle, R. A. Multiple myeloma: diagnosis and treatment. Mayo Clin. Proc. 80, 1371\u20131382 (2005).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrclinonc201163_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277\u2013300 (2010).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201163_CR4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","volume":"23","author":"O Landgren","year":"2009","unstructured":"Landgren, O. & Weiss, B. M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis. Leukemia 23, 1691\u20131697 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle, R. A. & Rajkumar, S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3\u20139 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR6","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR9","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483\u20132494 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565\u20131571 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR11","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487\u20132498 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR12","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 106, 4050\u20134053 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR13","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson, P. G. et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108, 3458\u20133464 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201163_CR15","doi-asserted-by":"crossref","first-page":"a42","DOI":"10.1182\/blood.V116.21.42.42","volume":"116","author":"M Cavo","year":"2010","unstructured":"Cavo, M. et al. Bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as induction and consolidation therapy before and after double autologous transplantation in newly diagnosed multiple myeloma: results from a randomized phase 3 study [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a42 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/83.10.1142","volume":"83","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar, S. V. Treatment of myeloma: cure vs control. Mayo Clin. Proc. 83, 1142\u20131145 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrclinonc201163_CR17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie, B. G. & Salmon, S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842\u2013854 (1975).","journal-title":"Cancer"},{"key":"BFnrclinonc201163_CR18","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR19","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca, R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210\u20132221 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","volume":"84","author":"SK Kumar","year":"2009","unstructured":"Kumar, S. K. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin. Proc. 84, 1095\u20131110 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrclinonc201163_CR21","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","volume":"23","author":"Y Zhou","year":"2009","unstructured":"Zhou, Y., Barlogie, B. & Shaughnessy, J. D. Jr . The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 23, 1941\u20131956 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR22","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR23","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","volume":"15","author":"SV Rajkumar","year":"2009","unstructured":"Rajkumar, S. V. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin. Cancer Res. 15, 5606\u20135608 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201163_CR24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","volume":"50","author":"M Hjorth","year":"1993","unstructured":"Hjorth, M. et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur. J. Haematol. 50, 95\u2013102 (1993).","journal-title":"Eur. J. Haematol."},{"key":"BFnrclinonc201163_CR25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","volume":"82","author":"A Riccardi","year":"2000","unstructured":"Riccardi, A. et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br. J. Cancer 82, 1254\u20131260 (2000).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201163_CR26","doi-asserted-by":"crossref","first-page":"a614","DOI":"10.1182\/blood.V114.22.614.614","volume":"114","author":"M-V Mateos","year":"2009","unstructured":"Mateos, M.-V. et al. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis [abstract]. Blood 114 (ASH Annual Meeting Abstracts), a614 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR27","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar, S. et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114, 1729\u20131735 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR28","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar, S. V. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20, 4319\u20134323 (2002).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"BFnrclinonc201163_CR29","first-page":"604a","volume":"94","author":"DM Weber","year":"1999","unstructured":"Weber, D. M. et al. Thalidomide alone or with dexamethasone for multiple myeloma [abstract]. Blood 94 (Suppl. 1), 604a (1999).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR30","first-page":"826","volume":"89","author":"M Cavo","year":"2004","unstructured":"Cavo, M. et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89, 826\u2013831 (2004).","journal-title":"Haematologica"},{"key":"BFnrclinonc201163_CR31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar, S. V., Blood, E., Vesole, D. H., Fonseca, R. & Greipp, P. R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431\u2013436 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar, S. V. et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26, 2171\u20132177 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR33","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","volume":"113","author":"H Ludwig","year":"2009","unstructured":"Ludwig, H. et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113, 3435\u20133442 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","volume":"115","author":"F Gay","year":"2010","unstructured":"Gay, F. et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115, 1343\u20131350 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR35","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989\u20131999 (2010).","journal-title":"Lancet"},{"key":"BFnrclinonc201163_CR36","doi-asserted-by":"crossref","first-page":"a492","DOI":"10.1182\/blood.V114.22.492.492","volume":"114","author":"A Palumbo","year":"2009","unstructured":"Palumbo, A. et al. A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens [abstract]. Blood 114 (ASH Annual Meeting Abstracts), a492 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo, A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414\u2013423 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR38","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","volume":"116","author":"JA Zonder","year":"2010","unstructured":"Zonder, J. A. et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116, 5838\u20135841 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR39","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar, S. et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21, 2035\u20132042 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR40","first-page":"1498","volume":"91","author":"JL Harousseau","year":"2006","unstructured":"Harousseau, J. L. et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91, 1498\u20131505 (2006).","journal-title":"Haematologica"},{"key":"BFnrclinonc201163_CR41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S Jagannath","year":"2005","unstructured":"Jagannath, S. et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 129, 776\u2013783 (2005).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201163_CR42","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005\u201301 phase III trial. J. Clin. Oncol. 28, 4621\u20134629 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos, M. V. et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11, 934\u2013941 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201163_CR44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1470-2045(10)70199-6","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. Optimising bortezomib in newly diagnosed multiple myeloma. Lancet Oncol. 11, 909\u2013910 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201163_CR45","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2007.15.2546","volume":"26","author":"J San-Miguel","year":"2008","unstructured":"San-Miguel, J., Harousseau, J. L., Joshua, D. & Anderson, K. C. Individualizing treatment of patients with myeloma in the era of novel agents. J. Clin. Oncol. 26, 2761\u20132766 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc201163_CR46","doi-asserted-by":"crossref","first-page":"a8014","DOI":"10.1200\/jco.2010.28.15_suppl.8014","volume":"28","author":"P Moreau","year":"2010","unstructured":"Moreau, P. et al. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone to bortezomib plus dexamethasone as induction treatment prior to ASCT in de novo multiple myeloma: Results of IFM2007\u201302 study [abstract]. J. Clin. Oncol. 28 (Suppl.), a8014 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679\u2013686 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR48","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2010)."},{"key":"BFnrclinonc201163_CR49","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder, C. B. et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23, 1337\u20131341 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR50","doi-asserted-by":"crossref","first-page":"a621","DOI":"10.1182\/blood-2010-06-290668","volume":"116","author":"S Kumar","year":"2010","unstructured":"Kumar, S. et al. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a621 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR51","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","volume":"115","author":"HM Lokhorst","year":"2010","unstructured":"Lokhorst, H.M. et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115, 1113\u20131120 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR52","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","volume":"27","author":"AJ Jakubowiak","year":"2009","unstructured":"Jakubowiak, A.J. et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J. Clin. Oncol. 27, 5015\u20135022 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie, B. et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol. 138, 176\u2013185 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201163_CR54","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","volume":"24","author":"SK Kumar","year":"2010","unstructured":"Kumar, S. K. et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 24, 1350\u20131356 (2010).","journal-title":"Leukemia"},{"issue":"Suppl. 2","key":"BFnrclinonc201163_CR55","first-page":"149","volume":"95","author":"S Jacobus","year":"2010","unstructured":"Jacobus, S. et al. Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide\/high-dose dexamethasone (RD) versus lenalidomide\/low-dose dexamethasone (Rd) [abstract 0370]. Haematologica 95 (Suppl. 2), 149 (2010).","journal-title":"Haematologica"},{"issue":"Suppl. 2","key":"BFnrclinonc201163_CR56","first-page":"153","volume":"95","author":"F Gay","year":"2010","unstructured":"Gay, F. et al. Safety and efficacy of lenalidomide plus dexamethasone in elderly newly diagnosed multiple myeloma patients 70 years of age and older [abstract 0379]. Haematologica 95 (Suppl. 2), 153 (2010).","journal-title":"Haematologica"},{"key":"BFnrclinonc201163_CR57","doi-asserted-by":"crossref","unstructured":"[No authors listed] Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J. Clin. Oncol. 16, 3832\u20133842 (1998).","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"BFnrclinonc201163_CR58","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR59","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","volume":"107","author":"T Facon","year":"2006","unstructured":"Facon, T. et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107, 1292\u20131298 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR60","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon, T. et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet 370, 1209\u20131218 (2007).","journal-title":"Lancet"},{"key":"BFnrclinonc201163_CR61","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin, C. et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J. Clin. Oncol. 27, 3664\u20133670 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR62","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825\u2013831 (2006).","journal-title":"Lancet"},{"key":"BFnrclinonc201163_CR63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","volume":"116","author":"A Waage","year":"2010","unstructured":"Waage, A. et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116, 1405\u20131412 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR64","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","volume":"28","author":"P Wijermans","year":"2010","unstructured":"Wijermans, P. et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J. Clin. Oncol. 28, 3160\u20133166 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR65","doi-asserted-by":"crossref","first-page":"a615","DOI":"10.1182\/blood-2009-01-202010","volume":"114","author":"P Kapoor","year":"2009","unstructured":"Kapoor, P. et al. Melphalan and prednisone (MP) versus melphalan, prednisone and thalidomide (MPT) as initial therapy for previously untreated elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis of randomized controlled trials [abstract]. Blood 114 (ASH Annual Meeting Abstracts), a615 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR66","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","volume":"108","author":"M-V Mateos","year":"2006","unstructured":"Mateos, M.-V. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study. Blood 108, 2165\u20132172 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906\u2013917 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR68","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"M-V Mateos","year":"2010","unstructured":"Mateos, M.-V. et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J. Clin. Oncol. 28, 2259\u20132266 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR69","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo, A. et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28, 5101\u20135109 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR70","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","volume":"25","author":"A Palumbo","year":"2007","unstructured":"Palumbo, A. et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2013Italian Multiple Myeloma Network. J. Clin. Oncol. 25, 4459\u20134465 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR71","doi-asserted-by":"crossref","first-page":"a622","DOI":"10.1182\/blood-2010-05-285155","volume":"116","author":"A Palumbo","year":"2010","unstructured":"Palumbo, A. et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u226565 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a622 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N. Engl. J. Med. 335, 91\u201397 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR73","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child, J. A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875\u20131883 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR74","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","volume":"83","author":"MA Gertz","year":"2008","unstructured":"Gertz, M. A. et al. Autologous stem cell transplantation in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplantation, and effect of a multidisciplinary quality initiative. Mayo Clin. Proc. 83, 1131\u20131138 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrclinonc201163_CR75","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie, B. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J. Clin. Oncol. 24, 929\u2013936 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"BFnrclinonc201163_CR76","first-page":"a2729","volume":"88","author":"T Facon","year":"1996","unstructured":"Facon, T. et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM) protocol [abstract]. Blood 88 (Suppl. 1), a2729 (1996).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR77","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand, J. P. et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92, 3131\u20133136 (1998).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR78","doi-asserted-by":"crossref","first-page":"a137","DOI":"10.1182\/blood-2003-01-0073","volume":"102","author":"J Blade","year":"2003","unstructured":"Blade, J. et al. High-dose therapy autotransplantation\/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: definitive results from PETHEMA after a median follow-up of 66 months [abstract]. Blood 102, a137 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR79","first-page":"a7","volume":"100","author":"M Attal","year":"2002","unstructured":"Attal, M. et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the \u201cIntergroupe Francophone du Myelome\u201d (IFM 94) [abstract]. Blood 100, a7 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR80","doi-asserted-by":"crossref","first-page":"a536","DOI":"10.1182\/blood.V104.11.536.536","volume":"104","author":"M Cavo","year":"2004","unstructured":"Cavo, M. et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma [abstract]. Blood 104, a536 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR81","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1200\/JCO.2010.31.5515","volume":"28","author":"JC Regelink","year":"2010","unstructured":"Regelink, J. C. et al. Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma. J. Clin. Oncol. 28, e741\u2013e743 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR82","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney, D. G. et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102, 3447\u20133454 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR83","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno, B. et al. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 356, 1110\u20131120 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201163_CR84","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F Garban","year":"2006","unstructured":"Garban, F. et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99\u201303 trial) with tandem autologous stem cell transplantation (IFM99\u201304 trial) in high-risk de novo multiple myeloma. Blood 107, 3474\u20133480 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR85","doi-asserted-by":"crossref","first-page":"a52","DOI":"10.1182\/blood.V114.22.52.52","volume":"114","author":"G Gahrton","year":"2009","unstructured":"Gahrton, G. et al. Tandem autologous(ASCT)\/ allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT [abstract]. Blood 114 (ASH Annual Meeting Abstracts), a52 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR86","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"L Rosi\u00f1ol","year":"2008","unstructured":"Rosi\u00f1ol, L. et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112, 3591\u20133593 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR87","doi-asserted-by":"crossref","first-page":"a41","DOI":"10.1182\/blood-2010-02-268466","volume":"116","author":"A Krishnan","year":"2010","unstructured":"Krishnan, A. et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a41 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR88","doi-asserted-by":"crossref","first-page":"a526","DOI":"10.1182\/blood.V116.21.526.526","volume":"116","author":"EA Stadtmauer","year":"2010","unstructured":"Stadtmauer, E. A. et al. Tandem autologous stem cell transplants (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling non-myeloablative allogeneic stem cell transplant (auto-allo) for patients (pts) with high risk (HR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 trial [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a526 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR89","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","volume":"13","author":"J Haessler","year":"2007","unstructured":"Haessler, J. et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin. Cancer Res. 13, 7073\u20137079 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201163_CR90","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair, B. et al. Superior results of Total Therapy 3 (2003\u20132033) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance. Blood 115, 4168\u20134173 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR91","doi-asserted-by":"crossref","first-page":"a40","DOI":"10.1182\/blood.V116.21.40.40","volume":"116","author":"P Sonneveld","year":"2010","unstructured":"Sonneveld, P. et al. HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a40 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR92","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal, M. et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108, 3289\u20133294 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR93","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","volume":"27","author":"A Spencer","year":"2009","unstructured":"Spencer, A. et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27, 1788\u20131793 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR94","doi-asserted-by":"crossref","first-page":"a39","DOI":"10.1182\/blood-2010-04-281212","volume":"116","author":"AK Stewart","year":"2010","unstructured":"Stewart, A. K. et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a39 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR95","doi-asserted-by":"crossref","first-page":"a310","DOI":"10.1182\/blood.V116.21.310.310","volume":"116","author":"M Attal","year":"2010","unstructured":"Attal, M. et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005\u201302 [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a310 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR96","doi-asserted-by":"crossref","first-page":"a37","DOI":"10.1182\/blood.V116.21.37.37","volume":"116","author":"PL McCarthy","year":"2010","unstructured":"McCarthy, P. L. et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a37 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR97","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar, S. K. et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. 79, 867\u2013874 (2004).","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl. 2","key":"BFnrclinonc201163_CR98","first-page":"151","volume":"95","author":"S Kumar","year":"2010","unstructured":"Kumar, S. et al. Outcome of patients with myeloma relapsing after IMiD and bortezomib therapy: a multicenter study from the International Myeloma Foundation Working Group [abstract 0376]. Haematologica 95 (Suppl. 2), 151 (2010).","journal-title":"Haematologica"},{"key":"BFnrclinonc201163_CR99","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","volume":"22","author":"RE Tiedemann","year":"2008","unstructured":"Tiedemann, R. E. et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 22, 1044\u20131052 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR100","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey, S. A. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22, 3269\u20133276 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR101","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy, M. Q. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27, 5008\u20135014 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201163_CR102","doi-asserted-by":"crossref","first-page":"a859","DOI":"10.1182\/blood-2010-04-281253","volume":"116","author":"X Leleu","year":"2010","unstructured":"Leleu, X. et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009\u201302 [abstract]. Blood 116 (ASH Annual Meeting Abstracts), a859 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR103","doi-asserted-by":"crossref","first-page":"a302","DOI":"10.1182\/blood.V114.22.302.302","volume":"114","author":"L Wang","year":"2009","unstructured":"Wang, L. et al. Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM) [abstract]. Blood 114 (ASH Annual Meeting Abstracts), a302 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201163_CR104","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/leu.2009.179","volume":"23","author":"JP Laubach","year":"2009","unstructured":"Laubach, J. P. et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23, 2222\u20132232 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201163_CR105","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.63","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:19:05Z","timestamp":1684451945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2011.63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,26]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["BFnrclinonc201163"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2011.63","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,26]]}}}